Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)

NCT01743157 is registered in ClinicalTrials.gov with California Pacific Medical Center Research Institute as lead sponsor.

NCT NCT01743157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01743157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)
Lead sponsor
California Pacific Medical Center Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2010
Completion date
May 31, 2013
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma